A Real World Study of Anti-PD-1/PD-L1 Antibodies for the Treatment of Advanced Solid Tumors

Chinese PLA General Hospital (301 Hospital)

Status: Unknown

Conditions: Advanced Solid Tumors

Treatments: Drug: Anti-PD-1/PD-L1 antibodies

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT03787953

PDL1-2018-301BJ

Details and patient eligibility

About

The study was designed to analyze the efficacy and safety of anti-PD-1/PD-L1 antibodies for the treatment of advanced solid tumors.

Full description

The study is a real-world study and the case records of patients with advanced solid tumors who visited Department of Medical Oncology, Chinese PLA General Hospital from 2015 to 2019 and received anti-PD-1/PD-L1 antibody therapy will be collected in this study. The medical data including patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, and so on will be extracted to analyze the effectivity and safety of anti-PD-1/PD-L1 antibodies and explore the prognosis-relevant factors of advanced solid tumors.

Enrollment: 400 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pathologically or cytologically confirmed advanced solid tumors;
• Received anti-PD-1/PD-L1 antibody therapy.

Exclusion criteria

• No specific exclusion criteria in this real world study.

Trial design

400 participants in 1 patient group

Anti-PD-1/PD-L1 antibodies

Description:

Patients with advanced solid tumors who visited Department of Medical Oncology, Chinese PLA General Hospital from 2015 to 2019 and received anti-PD-1/PD-L1 antibody therapy

Treatment:

Drug: Anti-PD-1/PD-L1 antibodies